Blood protein levels changed after bone drug in older women
Among 36 older women with low bone density, levels of about 400 blood proteins changed after zoledronate compared with levels before treatment.
Mice, dose-response
Limit: The human protein analysis gave no placebo comparison
Edited by Boris Djordjevic · AgingResearch.News
In 36 women over 65 with osteopenia, or low bone density, researchers analyzed blood samples from a randomized trial of zoledronate, a drug used to treat excessive bone loss. They measured proteins before treatment and 18 and 36 months after starting a 5 mg injection regimen.
Levels of about 400 proteins changed. Proteins linked to problems with DNA stability, protein maintenance and other aging-related processes decreased. Some proteins released by senescent cells, which have stopped dividing, also decreased. In a separate experiment, aged mice given zoledronate for two months showed shifts in cell composition toward young animals in the heart, liver and intestine. In human cells grown in the lab, low doses of several bisphosphonates stimulated growth and protected against DNA damage-induced senescence, with the strongest effects in heart muscle cells.
Why it matters
The work explores whether changes in aging-related processes could help explain the suggested benefits of bone-loss drugs outside the skeleton.
Caveats
The reported human protein analysis compared samples before and after treatment; the excerpts give no placebo comparison or adverse-event data for this analysis. These molecular findings do not establish slower aging or better health, or effects in men or younger people.
The paper
University of Oxford
Signal Transduction and Targeted Therapy, Jul 15, 2026, Open access
